Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 161

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

In vitro and in vivo characterization of PF‐04418948, a novel, potent and selective prostaglandin EP2receptor antagonist

Open access
af Forselles, KJ, Root, J, Clarke, T, Davey, D, Aughton, K, Dack, K, Pullen, N·2011·British Journal of Pharmacology

Abstract

BACKGROUND AND PURPOSE Studies of the role of the prostaglandin EP 2 receptor) have been limited by the availability of potent and selective antagonist tools. Here we describe the in vitro/in vivo pharmacological characterization of a novel EP 2 receptor antagonist, PF‐04418948 (1‐(4‐fluorobenzoyl)‐3‐{[(6‐methoxy‐2‐naphthyl)oxy]methyl} azetidine‐3‐carboxylic acid). EXPERIMENTAL APPROACH Functional antagonist potency was assessed in cell‐based systems expressing human EP 2 receptors and native tissue preparations from human, dog and mouse. The selectivity of PF‐04418948 was assessed against related receptors and a panel of GPCRs, ion channels and enzymes. The ability of PF‐04418948 to pharmacologically block EP 2 receptor function in vivo was tested in rats. KEY RESULTS PF‐04418948 inhibited prostaglandin E 2(PGE 2)‐induced increase in cAMP in cells expressing EP 2 receptors with a functional K B value of 1.8 nM. In human myometrium, PF‐04418948 produced a parallel, rightward shift of the butaprost‐induced inhibition of the contractions induced by electrical field stimulation with an apparent K B of 5.4 nM. In dog bronchiole and mouse trachea, PF‐04418948 produced parallel rightward shifts of the PGE 2‐induced relaxation curve with a K B of 2.5 nM and an apparent K B of 1.3 nM respectively. Reversal of the PGE 2‐induced relaxation in the mouse trachea by PF‐04418948 produced an IC 50 value of 2.7 nM. Given orally, PF‐04418948 attenuated the butaprost‐induced cutaneous blood flow response in rats. PF‐04418948 was selective for EP 2 receptors over homologous and unrelated receptors, enzymes and channels. CONCLUSIONS AND IMPLICATIONS PF‐04418948 is an orally active, potent and selective surmountable EP 2 receptor antagonist that should aid further elaboration of EP 2 receptor function. LINKED ARTICLE This article is commented on by Birrell and Nials, pp. 1845–1846 of this issue. To view this commentary visit http://dx.doi.org/10.1111/j.1476‐5381.2011.01494.x

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1476-5381.2011.01495.x

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 161

Metadata

Authors
af Forselles, K., Root, J., Clarke, T., Davey, D., Aughton, K., Dack, K., & Pullen, N.
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2011-11-15
Volume
164
Issue
7
Pages
1847-1856
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W1738485982
Cited by
161
References
1
FWCI
7.09
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: In vitro and in vivo characterization of PF‐04418948, a novel, potent and selective prostaglandin EP2receptor antagonist. https://app.cochat.ai/papers/10.1111/j.1476-5381.2011.01495.x
The paper
af Forselles, K., Root, J., Clarke, T., Davey, D., Aughton, K., Dack, K., & Pullen, N. (2011). In vitro and in vivo characterization of PF‐04418948, a novel, potent and selective prostaglandin EP2receptor antagonist. British Journal of Pharmacology. https://doi.org/10.1111/j.1476-5381.2011.01495.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.